Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Measles outbreaks have hit multiple U.S. states, vaccination & rapid reporting are critical to limit the spread & hospitalizations ...

Ready to make your own sausages at home? Check out our selection of 22 DIY sausage making kits, recipes and products.

ZEPBOUND ™ KwikPen ® is the first and only Health Canada-approved treatment activating two incretin hormone receptors, GIP and GLP-1, to manage obesity or overweight Adults taking tirzepatide ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.